Pioglitazone Heart Failure Risk: What Patients with MASLD Need to Know

How Pioglitazone Causes Fluid Retention and Heart Failure

Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma) in renal collecting duct cells, which upregulates epithelial sodium channels and promotes sodium and water reabsorption [7]. The result is plasma volume expansion of roughly 6 to 7% at the 45 mg dose. In a healthy heart that expansion is well tolerated. In a ventricle already working against elevated filling pressures, it tips the balance toward decompensated failure.

The PROactive trial (N=5,238 patients with type 2 diabetes and established cardiovascular disease) randomised participants to pioglitazone 45 mg or placebo for a mean 34.5 months [1]. Serious heart failure events occurred in 5.7% of the pioglitazone arm versus 4.1% in the placebo arm, a statistically significant difference (P<0.0001). Heart failure hospitalisation was the most commonly reported serious adverse event in that trial. Critically, PROactive patients had pre-existing atherosclerotic disease. The absolute risk in a lower-risk MASLD population is smaller but cannot be dismissed, particularly because MASLD itself is associated with subclinical diastolic dysfunction even before overt cardiovascular disease appears [8].

The FDA issued a black-box warning in 2007: pioglitazone is contraindicated in patients with established NYHA Class III or IV heart failure [9]. Initiation is not recommended in any patient with symptomatic heart failure, and the label specifically states that treatment should be discontinued if any deterioration in cardiac status occurs.

Who Is at Highest Risk

Not every MASLD patient carries equal cardiac risk. Three groups face disproportionate danger.

Existing left ventricular dysfunction. Echocardiographic data from the ARIC cohort (N=14,543) show that MASLD is independently associated with a 34% higher prevalence of diastolic dysfunction even after adjustment for body mass index and metabolic syndrome [8]. Prescribing pioglitazone before screening for subclinical dysfunction means some patients start treatment with a ventricle already compromised.

Older patients with hypertension. Age above 65 and longstanding hypertension both thicken the left ventricular wall, reducing compliance. A meta-analysis of nine randomised controlled trials (N=9,997) found that the odds of heart failure hospitalisation with thiazolidinediones were highest in patients over 65 (OR 2.1 to 95% CI 1.6, 2.8) [10].

Patients on insulin or insulin secretagogues. Combining pioglitazone with insulin increases fluid retention risk further. The PROactive substudy showed that patients on background insulin who received pioglitazone had a 6.1% rate of serious heart failure versus 4.3% in those not on insulin [1]. The FDA label explicitly warns that combination with insulin may require dose reduction of the insulin to reduce hypoglycaemia and oedema [9].

The Liver Benefit: Is It Worth the Cardiac Risk in MASLD?

Pioglitazone's liver benefit in NASH is well documented. The PIVENS trial (N=247 to 96 weeks) found that 45 mg daily improved the NAFLD Activity Score by at least two points in 34% of treated patients versus 19% on placebo, and fibrosis improved in 47% versus 21% [2]. A separate Cochrane systematic review of eight randomised trials confirmed histological improvement in steatosis, inflammation, and ballooning, although the fibrosis benefit was less consistent across all studies [11].

The AASLD 2023 Practice Guidance states: "Pioglitazone (45 mg/day) is recommended for patients with biopsy-proven NASH with fibrosis stage F2 or greater, provided cardiovascular risk has been assessed and the drug is not contraindicated" [6]. That caveat about cardiovascular assessment is not cosmetic. The guidance links directly to the FDA black-box warning and recommends baseline echocardiography or brain natriuretic peptide (BNP) measurement before starting treatment.

The framework below synthesises AASLD 2023, FDA labelling, and the PROactive data into a four-step pre-prescribing checklist:

1. Exclude NYHA Class III, IV heart failure. If present, do not prescribe.
2. Obtain baseline BNP or NT-proBNP. A BNP above 100 pg/mL warrants cardiology referral before starting.
3. Screen for diastolic dysfunction. Echocardiography is preferred in patients over 60, with hypertension, or with a prior hospitalisation for any cardiac event.
4. Document baseline weight. Weight gain exceeding 2 kg within the first four weeks of treatment is an early signal of fluid accumulation and should prompt dose reduction from 45 mg to 30 mg or drug discontinuation.

For patients who clear all four checkpoints, 45 mg daily for at least 96 weeks is the dose and duration supported by PIVENS [2]. Shorter courses or lower doses show attenuated histological benefit.

Monitoring Pioglitazone Safely During MASLD Treatment

Monitoring frequency matters as much as the baseline workup. Body weight is the simplest and most sensitive early signal: a gain of more than 3 to 4 kg over the first 8 to 12 weeks should trigger clinical reassessment [3]. Ankle oedema is the other common early sign, reported in 4.8% of pioglitazone-treated patients in PROactive versus 1.3% on placebo [1].

BNP monitoring at three and six months identifies patients developing subclinical volume overload before symptoms emerge. A study of 312 diabetic patients on pioglitazone found that BNP rose significantly in the subgroup with pre-existing echocardiographic E/e' ratio above 10, while remaining stable in those with normal diastolic function [12]. That finding supports targeted monitoring rather than universal echocardiography at every follow-up.

Liver enzymes (ALT, AST) should also be checked at baseline, three months, and six months. Although pioglitazone rarely causes direct hepatotoxicity, a rise in ALT to more than three times the upper limit of normal during treatment warrants re-evaluation of the diagnosis and review of other medications [6].

Bone fracture risk deserves mention. A meta-analysis of 10 trials (N=13,715) reported a relative risk of 1.45 for fractures in women on thiazolidinediones compared with controls [13]. The mechanism involves reduced osteoblast differentiation mediated by PPAR-gamma activation in bone marrow stromal cells. Women with MASLD who are postmenopausal and already at elevated fracture risk should receive a DEXA scan before starting treatment and annually thereafter.

Resmetirom: The Newer Option and Its Side-Effect Profile

Resmetirom (Rezdiffra, Madrigal Pharmaceuticals) received FDA approval in March 2024 as the first drug specifically approved to treat NASH with moderate-to-advanced fibrosis (F2, F3) in adults with obesity or overweight [4]. Its mechanism is entirely different: it is a selective thyroid hormone receptor beta (THR-beta) agonist that reduces hepatic de novo lipogenesis without the cardiac fluid-retention risk of pioglitazone.

The MAESTRO-NASH trial (N=966 to 52 weeks) showed that resmetirom 80 mg achieved NASH resolution in 25.9% versus 14.2% placebo, and resmetirom 100 mg achieved 29.9% versus 14.2% [14]. Fibrosis improvement of at least one stage occurred in 24.2% (80 mg) and 25.9% (100 mg) versus 14.2% placebo [14].

Resmetirom side effects are primarily gastrointestinal. Nausea occurred in 20 to 26% of treated patients, diarrhoea in 18 to 21%, and pruritus in approximately 8 to 9% [14]. No increase in heart failure events, oedema, or fluid retention was seen in MAESTRO-NASH, which is the key differentiating factor from pioglitazone. The drug does carry a warning about potential interaction with statins: resmetirom increases exposure to rosuvastatin by approximately 3.6-fold via OATP1B1/1B3 inhibition, and statin doses should be capped according to the Rezdiffra prescribing information [4].

Resmetirom does not currently have long-term cardiovascular outcomes data comparable to PROactive. The MAESTRO-NASH OLE (open-label extension) is ongoing and will provide 96-week and 144-week safety data. Prescribers choosing between pioglitazone and resmetirom in a patient with cardiac risk factors should strongly favour resmetirom on current evidence.

Obeticholic Acid and the Pruritus Problem

Obeticholic acid (OCA, Ocaliva) is a farnesoid X receptor (FXR) agonist that reduces hepatic bile acid synthesis and inflammation. In the REGENERATE trial (N=2,477 to 18 months), OCA 25 mg produced fibrosis improvement of at least one stage in 23% of patients versus 12% on placebo [5]. Those numbers are meaningful. The drug did not receive full FDA approval for NASH because of concerns about the clinical benefit endpoint, but it remains a treatment studied in multiple ongoing trials.

The dominant side effect of obeticholic acid is pruritus. In REGENERATE, pruritus occurred in 51% of patients receiving OCA 25 mg and 28% receiving OCA 10 mg, compared with 19% on placebo [5]. Rates of severe or very severe pruritus were 11% and 6% respectively. Discontinuation due to pruritus reached 9% in the 25 mg group. The mechanism involves FXR-mediated changes in bile acid composition and possible direct activation of skin sensory neurons via lysophosphatidic acid accumulation [15].

Managing OCA-associated pruritus requires dose titration: starting at 10 mg daily and escalating to 25 mg only after 3 months, if tolerated. Bile acid sequestrants such as cholestyramine taken four hours before or after OCA can reduce pruritus severity without neutralising the drug's efficacy. Rifampicin 150 mg twice daily has been used in refractory cases, though it carries its own hepatotoxicity risk and requires careful liver enzyme monitoring [16].

Patients with cirrhosis (F4) should not receive OCA at the 25 mg dose due to a risk of hepatic decompensation. The REGENERATE trial excluded patients with Child-Pugh B or C disease, and a post-marketing signal of decompensation in cirrhotic patients led to an FDA safety communication in 2021 [9].

Comparing the Three Agents: Pioglitazone, Resmetirom, and Obeticholic Acid

Choosing among these three agents requires matching the drug's risk profile to the patient's comorbidities.

| Feature | Pioglitazone | Resmetirom | Obeticholic Acid | |---|---|---|---| | FDA approval for NASH | Off-label (AASLD-recommended) | Yes (F2, F3, March 2024) | No (REGENERATE pending) | | Fibrosis improvement rate | 47% (PIVENS) [2] | 24 to 26% (MAESTRO-NASH) [14] | 23% (REGENERATE) [5] | | Heart failure risk | Doubled hospitalisation rate [1] | No signal in MAESTRO-NASH [14] | Not reported as concern | | Pruritus rate | <2% | 8 to 9% [14] | 51% at 25 mg [5] | | Weight effect | +3 to 5 kg [3] | Neutral to mild reduction | Neutral | | Key contraindication | NYHA III, IV HF, active bladder cancer | Severe hepatic impairment | Child-Pugh B/C cirrhosis |

For a MASLD patient with fibrosis F2, F3, no cardiac history, and no cirrhosis, resmetirom is the only FDA-approved option and avoids both the cardiac risk of pioglitazone and the pruritus burden of OCA. For a patient with fibrosis F2, F3, type 2 diabetes, normal echocardiography, and normal BNP who cannot afford resmetirom (list price approximately $47,000/year), pioglitazone at 45 mg remains a reasonable off-label choice supported by AASLD guidelines [6], provided monitoring is rigorous.

Special Populations: Type 2 Diabetes, Obesity, and Post-Bariatric Patients

MASLD occurs alongside type 2 diabetes in approximately 55 to 70% of cases [17]. Pioglitazone has the unique advantage of addressing both conditions simultaneously. Its glucose-lowering effect is modest (HbA1c reduction of approximately 0.5 to 1.4% depending on baseline) but its insulin-sensitising action in liver and adipose tissue is directly relevant to MASLD pathophysiology [3].

Bariatric surgery achieves NASH resolution in 85% of patients at 12 months in prospective series, and fibrosis improvement in 40 to 50% [18]. Patients who are post-bariatric and have residual MASLD with fibrosis may not absorb pioglitazone reliably after Roux-en-Y gastric bypass due to altered gastric emptying and intestinal transit. Plasma levels may be reduced by 30 to 40% in that setting, making therapeutic drug monitoring or switching to resmetirom more appropriate.

GLP-1 receptor agonists such as semaglutide 2.4 mg (Wegovy) showed NASH resolution in 59% of patients at 72 weeks in a phase 2 trial (N=320) [19], with a phase 3 ESSENCE trial currently enrolling. Semaglutide carries no heart failure contraindication and in the SELECT trial (N=17,604) actually reduced major adverse cardiovascular events by 20% versus placebo [20]. For MASLD patients with obesity and type 2 diabetes who also have cardiac risk, semaglutide may be the preferable bridge or alternative to pioglitazone while NASH-specific approvals mature.

Key Drug Interactions to Know

Pioglitazone is primarily metabolised by CYP2C8 and, to a lesser extent, CYP3A4 [9]. Gemfibrozil, a strong CYP2C8 inhibitor, increases pioglitazone AUC by approximately 3.4-fold and should not be co-administered [9]. Rifampicin, a CYP2C8 inducer, reduces pioglitazone exposure by 54% and would undermine therapeutic efficacy [9].

Resmetirom's statin interaction is the most clinically significant drug-drug interaction for MASLD patients, who are frequently on lipid-lowering therapy. Rosuvastatin 40 mg should be reduced to a maximum of 10 mg when co-administered with resmetirom [4]. Simvastatin and lovastatin AUC increases are more modest but still warrant dose review.

Obeticholic acid inhibits CYP3A4 at high concentrations and modestly increases exposure to warfarin and other CYP3A4 substrates. INR monitoring should be more frequent during OCA initiation in anticoagulated patients [16].

Practical Prescribing Checklist Before Starting Pioglitazone for MASLD

The following steps should be completed before the first prescription is written.

Confirm biopsy or non-invasive fibrosis staging shows F2 or greater. AASLD 2023 does not recommend pioglitazone for steatosis alone without significant inflammation or fibrosis [6]. Obtain a resting ECG and BNP. Order a fasting lipid panel because pioglitazone raises HDL by 10 to 15% but also raises LDL by a small amount in some patients [3]. Document absence of active bladder cancer (FDA black-box warning, added 2011, based on a 10-year epidemiological study showing HR 1.2 for bladder cancer with pioglitazone use exceeding 24 months) [9]. Assess fracture risk in postmenopausal women and consider DEXA. Review all concurrent medications for CYP2C8 interactions.

At the first follow-up visit (four weeks), measure weight and check for ankle oedema. If weight has increased by more than 2 kg, check BNP before continuing. At three months, repeat liver enzymes and BNP. At six months, repeat liver enzymes, BNP, and a fasting lipid panel. Continue this schedule every six months thereafter for the duration of treatment.

The minimum effective treatment duration for histological benefit is 96 weeks based on PIVENS [2]. Stopping at 48 weeks is associated with partial regression of histological improvement in observational follow-up data [6].